Strides Pharma Science · NSE: STAR · BSE: 532531

Q1 FY25 results · Apr–Jun 2024

Strides Pharma Science reported revenue from operations of ₹1,087.51 crore (up 16.9% from Q1 FY24) and net profit of ₹68.31 crore for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.

Consolidated · ₹ crore
Item	Q1 FY25	Q1 FY24	YoY	Q4 FY24	QoQ
Revenue from operations	1,087.51	929.99	+16.9%	1,084.04	+0.3%
Other income	12.72	8.64	+47.1%	(13.55)	Turned profit
Total income	1,100.22	938.64	+17.2%	1,070.49	+2.8%
Profit before share of associates & JVs and tax	96.98	33.25	+191.7%	78.20	+24.0%
Share of profit/(loss) of associates & JVs	(11.80)	(32.93)		(48.58)
Net profit for the period	68.31	(9.36)	Turned profit	10.44	+554.1%
Attributable to shareholders of the company	70.20	(7.11)	Turned profit	18.18	+286.3%
EPS, basic (₹)	7.64	(0.79)	Turned profit	1.98	+285.9%
Net margin (%)	6.3	-1.0		1.0

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q1 FY25	Q1 FY24	YoY	Q4 FY24	QoQ
Revenue from operations	554.75	475.32	+16.7%	617.63	−10.2%
Other income	11.83	11.65	+1.6%	29.63	−60.1%
Total income	566.58	486.97	+16.3%	647.27	−12.5%
Profit before tax	5.66	9.13	−38.0%	52.78	−89.3%
Net profit for the period	3.92	8.00	−51.0%	53.66	−92.7%
EPS, basic (₹)	0.43	0.89	−51.7%	5.84	−92.6%
Net margin (%)	0.7	1.7		8.7

Consolidated

Filed with BSE: 30 Jul 2024, 14:16 IST
Board meeting: 29 Jul 2024
Period: 01 Apr 2024 to 30 Jun 2024
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 30 Jul 2024, 14:16 IST
Board meeting: 29 Jul 2024
Period: 01 Apr 2024 to 30 Jun 2024
Review status: Unaudited
Source: XBRL filing on BSE